Yan Qin Tang
Président chez Robeco Teda (Tianjin) Investment Management Co. Ltd.
Profil
Mr. Yan Qin Tang is Independent Non-Executive Director at Mingyuan Medicare Development Co. Ltd., Vice President at China Health Insurance Research Association, Chairman at Lianhe Credit Information Service Co. Ltd., Chairman at Robeco Teda (Tianjin) Investment Management Co. Ltd., and Vice President at China Association For Labor Studies.
He is on the Board of Directors at Mingyuan Medicare Development Co. Ltd.
He received his undergraduate degree from Tianjin University.
Postes actifs de Yan Qin Tang
| Sociétés | Poste | Début |
|---|---|---|
| China Health Insurance Research Association | Corporate Officer/Principal | 15/09/2011 |
| Lianhe Credit Information Service Co. Ltd. | Président | 15/09/2011 |
| Robeco Teda (Tianjin) Investment Management Co. Ltd. | Président | 15/09/2011 |
| China Association For Labor Studies | Corporate Officer/Principal | - |
Anciens postes connus de Yan Qin Tang
| Sociétés | Poste | Fin |
|---|---|---|
| MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Directeur/Membre du Conseil | 16/12/2014 |
Formation de Yan Qin Tang
| Tianjin University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Mingyuan Medicare Development Co. Ltd.
 Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
| China Health Insurance Research Association | |
| Lianhe Credit Information Service Co. Ltd. | |
| Robeco Teda (Tianjin) Investment Management Co. Ltd. | |
| China Association For Labor Studies |
